Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821117 | 0.80 | KDM4E (0.68) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL458012 | 0.80 | KDM4E (0.68) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL5307853 | 0.80 | — | — | |
| SCHEMBL3624681 | 0.80 | KDM4E (0.68) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL4138147 | 0.79 | HSD17B10 (0.50) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| Hydrochloric Acid SCHEMBL19148315 | 0.77 | HSD17B10 (0.48) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL7345543 | 0.77 | KMT2A (0.36) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL12226477 | 0.77 | KMT2A (0.40) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL16118877 | 0.77 | KMT2A (0.36) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL1259867 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | VTV THERAPEUTICS LLC | 2021-11-04 | — | — | US | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210283111-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC | 2021-09-16 | — | — | US | disclosed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2018-10-11 | — | — | US | disclosed |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2536285-B1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3019492-B1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | disclosed |
| US-8759535-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | KDM4E 2451/4885TSHR 3357/4885POLB 2487/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KDM4E 2451/4885TSHR 3357/4885POLB 2487/4885 |
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | KDM4E 905/4885TSHR 1749/4885POLB 3557/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | KDM4E 2332/4885TSHR 3389/4885POLB 2872/4885 |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | HBB, HBG1, HBG2 | KDM4E 3590/4885TSHR 4199/4885POLB 1224/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KDM4E 2451/4885TSHR 3357/4885POLB 2487/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | KDM4E 276/4885TSHR 2548/4885POLB 3946/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | KDM4E 2569/4885TSHR 4206/4885POLB 811/4885 |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | KDM4E 2243/4885TSHR 3533/4885POLB 2190/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | KDM4E 905/4885TSHR 1749/4885POLB 3557/4885 |
| US-20210283111-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | NFATC1, CTSF, CTSB | KDM4E 750/4885TSHR 3816/4885POLB 4268/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | KDM4E 2711/4885TSHR 3693/4885POLB 1403/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KDM4E 1906/4885TSHR 705/4885POLB 1480/4885 |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | KDM4E 2243/4885TSHR 3533/4885POLB 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.